Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Endeavour Silver Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $19.17 (market cap $3.41B), while Endeavour Silver Corp trades at $8.62 (market cap $2.53B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Endeavour Silver Corp is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ACADIA Pharmaceuticals Inc. for 77 Days and Endeavour Silver Corp for 25 Days on average.
| ACAD | EXK | |
|---|---|---|
Market Cap | $3.41B | $2.53B |
Volume | 1,470,247 | 3,503,244 |
Sector | Health | Basic Materials |
52-Week High | $30.57 | $14.12 |
52-Week Low | $19.41 | $7.07 |
Typical Hold Time | 77 Days | 25 Days |
Enterprise Value | $2.53B | $2.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $19.78, up 1.02% today, amid mixed signals. The stock shows strong fundamental improvement with 2025 revenue reaching $1.07B and net income of $391M, yielding a net margin of 36.49%. However, technical indicators are bearish, and recent Phase II Alzheimer's trial results for remlifanserin missed the primary endpoint, causing volatility. Positive developments include European approval for Daybue and a patent extension to 2041.
The outlook is cautiously optimistic. Strong profitability and analyst consensus (70% buy ratings) with a $32.32 price target suggest upside potential, but clinical trial setbacks and a bearish technical trend present near-term risks. Investment appeal hinges on successful Phase III development of remlifanserin and continued commercial execution.
Endeavour Silver (EXK) trades at $8.65, up 0.93% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal from moving averages, though oscillators are neutral. Fundamentally, the company reported a net loss of $119.1 million for 2025 but is projected to swing to a $66 million profit in 2026, with revenue nearly doubling. Recent news highlights operational progress at key mines but also temporary disruptions.
The outlook is cautiously optimistic, driven by projected earnings growth and expansion projects like Terronera. However, risks include operational volatility, high valuation multiples, and sensitivity to silver prices. Analyst consensus is strongly bullish with 11 buy ratings, but investors should weigh near-term execution risks against long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
